Accuracy of point-of-care crossmatching methods and crossmatch incompatibility in critically ill dogs.

BACKGROUND: The performance of commercial point-of-care crossmatch (CM) tests compared to laboratory tube agglutination CM is unknown. Additionally, there is limited information regarding CM incompatibility in ill dogs. OBJECTIVES: To determine if point-of-care major CM methods are accurate in detecting compatible and incompatible tests when compared to laboratory CM methods, and to identify factors associated with CM incompatibility in dogs. ANIMALS: Part 1 (prospective) included 63 client-owned dogs potentially requiring blood transfusion. Part 2 (retrospective) included all dogs from part 1, plus medical records of 141 dogs with major CM results. METHODS: For part 1, major CM was performed using a tube agglutination assay (LAB-CM), a gel-based point-of-care test (GEL-CM), and an immunochromatographic point-of-care test (IC-CM). For part 2, medical record data were collected to determine rates of and risk factors for CM incompatibility. RESULTS: Kappa agreement between the LAB-CM and GEL-CM methods could not be calculated due to a relative lack of incompatible results. Kappa agreement between the LAB-CM and IC-CM methods was 0.16 (95% confidence interval [CI] = 0-0.31, P = .007) indicating no agreement. The LAB-CM incompatibility in transfusion-naïve vs dogs that had a transfusion was 25% and 35%, (P = .3). CONCLUSIONS AND CLINICAL IMPORTANCE: Compared to laboratory methods, point-of-care methods evaluated in our study lacked sensitivity for detecting incompatibilities. Dogs had similar rates of major CM incompatibility regardless of transfusion history. This suggests CM testing prior to transfusion be considered in all dogs however our study did not investigate clinical relevancy of incompatible LAB-CM.

Quadriceps Tendon Autograft for Primary Anterior Cruciate Ligament Reconstruction: A Systematic Review of Comparative Studies With Minimum 2-Year Follow-Up.

PURPOSE: To systematically review the literature in an effort to compare outcomes of patients undergoing primary anterior cruciate ligament reconstruction (ACLR) with a quadriceps tendon (QT) autograft versus a bone-patellar tendon-bone (BPTB) or hamstring tendon (HT) autograft. METHODS: A systematic review was performed by searching PubMed, the Cochrane Library, and Embase to locate studies (Level of Evidence I-III) comparing the clinical outcomes of the QT autograft versus the BPTB or HT autograft in patients undergoing primary ACLR. Patients were evaluated based on graft failure rate, examination of knee laxity, and patient-reported outcome scores. RESULTS: Eight studies (1 Level II, 7 Level III) were identified that met inclusion criteria, including a total of 368 patients undergoing primary ACLR with a QT autograft, 225 with a BPTB autograft, and 150 with an HT autograft. The average follow-up duration for all patients was 2.9 years. Overall, 2.8% of patients (17/603) experienced graft failure. Within the studies that compared the QT versus BPTB autograft, no study found a significant difference in graft failure rate between groups, and the odds ratio for graft failure between QT and BPTB was found to be 1.58 (95% confidence interval: 0.49-5.07; P = .44). Within the studies that compared graft failure rate between the QT and HT autograft, none found significant differences between groups, although a meta-analysis was not performed because of a low number of trials. Two studies found significantly greater postoperative knee laxity in HT patients compared with QT patients (P < .05), although there were no significant differences found in laxity measurements between QT and BPTB patients. CONCLUSIONS: Patients undergoing primary ACLR with either a QT, BPTB, or HT autograft can all be expected to experience improvement in clinical outcomes. QT patients experienced less knee laxity postoperatively compared with HT patients, although no significant differences were found in graft failure rate between groups. LEVEL OF EVIDENCE: Level III, systematic review of Level II and III studies.

Estrogen-induced myelotoxicity in a 4-year-old golden retriever dog due to a Sertoli cell tumor.

A 4-year-old, unilateral cryptorchid golden retriever dog was presented to the Ontario Veterinary College Health Sciences Centre with gynecomastia, dribbling urine, lethargy, neutropenia, and thrombocytopenia. A Sertoli cell tumor was diagnosed in a cryptorchid testicle with estrogen-induced myelotoxicity. The tumor was removed and bone marrow regenerated within 4 months.

Myélotoxicité induite par l'oestrogène chez un chien Golden retriever âgé de 4 ans causée par une tumeur à cellules de Sertoli. Un chien Golden retriever âgé de 4 ans avec cryptorchidie unilatérale a été présenté au Centre des sciences de la santé de l'Ontario Veterinary College atteint de gynécomastie, d'incontinence urinaire, de léthargie, de neutropénie et de thrombocytopénie. Une tumeur à cellules de Sertoli a été diagnostiquée dans un testicule cryptorchide avec de la myélotoxicité induite par l'oestrogène. La tumeur a été excisée et la moelle osseuse s'est régénérée dans un délai de 4 mois.(Traduit par Isabelle Vallières).

The Effect of Regular-Season Rest on Playoff Performance Among Players in the National Basketball Association.

BACKGROUND: There has been speculation that rest during the regular season for players in the National Basketball Association (NBA) improves player performance in the postseason. PURPOSE: To determine whether there is a correlation between the amount of regular-season rest among NBA players and playoff performance and injury risk in the same season. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: The Basketball Reference and Pro Sports Transactions archives were searched from the 2005 to 2015 seasons. Data were collected on players who missed fewer than 5 regular-season games because of rest (group A) and 5 to 9 regular-season games because of rest (group B) during each season. Inclusion criteria consisted of players who played a minimum of 20 minutes per game and made the playoffs that season. Players were excluded if they missed ≥10 games because of rest or suspension or missed ≥20 games in a season for any reason. Matched pairs were formed between the groups based on the following criteria: position, mean age at the start of the season within 2 years, regular-season minutes per game within 5 minutes, same playoff seeding, and player efficiency rating (PER) within 2 points. The following data from the playoffs were collected and compared between matched pairs at each position (point guard, shooting guard, forward/center): points per game, assists per game, PER, true shooting percentage, blocks, steals, and number of playoff games missed because of injury. RESULTS: A total of 811 players met the inclusion and exclusion criteria (group A: n = 744 players; group B: n = 67 players). Among all eligible players, 27 matched pairs were formed. Within these matched pairs, players in group B missed significantly more regular-season games because of rest than players in group A (6.0 games vs 1.3 games, respectively; P < .0001). There were no significant differences between the groups at any position in terms of points per game, assists per game, PER, true shooting percentage, blocks, steals, or number of playoff games missed because of injury. CONCLUSION: Rest during the NBA regular season does not improve playoff performance or affect the injury risk during the playoffs in the same season.